Study Phase 3

An Open-Label Prospective Trial to Explore the Tolerability, Safety and Efficacy of Flexibly-Dosed Paliperidone ER among Treatment-Naive and Newly Diagnosed Patients with Schizophrenia

  • 1 CSR Summary Not Available
  • 1 NCT01606228
  • 1 Primary Citation Trial has yet to be published
  • Data Specification Not Available

Trial Information

Generic NamePaliperidoneProduct NameINVEGA®Therapeutic AreaBehaviors and Mental DisordersEnrollment188% FemaleN/A% WhiteN/A
Product ClassAtypical AntipsychoticsSponsor Protocol NumberR076477SCH3033Data PartnerJohnson & JohnsonCondition StudiedSchizophreniaMean/Median Age (Years)N/A

Supporting Documentation

  • Protocol with Amendments Available
  • Statistical Analysis Plan Available
  • Clinical Study Report Available
Additional Information

Please note: individual participant-level data are not available for this trial. Only the protocol, statistical analysis plan, and clinical study report are available.

Approved Data Requests Associated with this Trial

Disclaimer

Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.